Eagle Pharmaceuticals
EGRX
#9808
Rank
S$61.56 M
Marketcap
S$4.75
Share price
0.00%
Change (1 day)
-29.89%
Change (1 year)

Revenue for Eagle Pharmaceuticals (EGRX)

Revenue in 2023 (TTM): S$0.35 Billion

According to Eagle Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is S$0.33 Billion. In 2022 the company made a revenue of S$0.42 Billion an increase over the revenue in the year 2021 that were of S$0.23 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Eagle Pharmaceuticals from 2013 to 2023

Annual revenue

Year Revenue Change
2023 (TTM) S$0.35 B-17.17%
2022 S$0.42 B83.02%
2021 S$0.23 B-6.66%
2020 S$0.24 B-5.92%
2019 S$0.26 B-9.37%
2018 S$0.29 B-7.95%
2017 S$0.31 B15.45%
2016 S$0.27 B192.74%
2015 S$93.68 M269.12%
2014 S$25.37 M13.25%
2013 S$22.41 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Johnson & Johnson
JNJ
S$115.01 B 34,584.78%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
S$52.25 B 15,658.66%๐Ÿ‡ฌ๐Ÿ‡ง UK
Novartis
NVS
S$68.52 B 20,564.65%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Teva Pharmaceutical Industries
TEVA
S$21.39 B 6,351.15%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Amgen
AMGN
S$43.93 B 13,150.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$63.09 B 18,926.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$61.33 B 18,395.75%๐Ÿ‡บ๐Ÿ‡ธ USA